Improved outcomes in stroke thrombolysis with pre-specified imaging criteria

B. Silver, Bart M Demaerschalk, J. G. Merino, E. Wong, A. Tamayo, A. Devasenapathy, C. O'Callaghan, A. Kertesz, G. B. Young, A. J. Fox, J. D. Spence, V. Hachinski

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: A 1995 National Institute of Neurological Disorders (NINDS) study found benefit for intravenous tissue plasminogen activator (tPA) in acute ischemic stroke (AIS). The symptomatic intracranial hemorrhage (SICH) rate in the NINDS study was 6.4%, which may be deterring some physicians from using this medication. Methods: Starting December 1, 1998, patients with AIS in London, Ontario were treated according to NINDS criteria with one major exception; those with approximately greater than one-third involvement of the idealized middle cerebral artery (MCA) territory on neuroimaging were excluded from treatment. The method used to estimate involvement of one-third MCA territory involvement bears the acronym ICE and had a median kappa value of 0.80 among five physicians. Outcomes were compared to the NINDS study. Results: Between December 1, 1998 and February 1,2000, 30 patients were treated. Compared to the NINDS study, more London patients were treated after 90 minutes (p<0.00001) and tended to be older. No SICH was observed. Compared to the treated arm of the NINDS trial, fewer London patients were dead or severely disabled at three months (p=0.04). Compared to the placebo arm of the trial, more patients made a partial recovery at 24 hours (p=0.02), more had normal outcomes (p=0.03) and fewer were dead or severely disabled at three months (p=0.004). Conclusions: The results of the NINDS study were closely replicated and, in some instances, improved upon in this small series of Canadian patients, despite older age and later treatment. These findings suggest that imaging exclusion criteria may optimize the benefits of tPA.

Original languageEnglish (US)
Pages (from-to)113-119
Number of pages7
JournalCanadian Journal of Neurological Sciences
Volume28
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Nervous System Diseases
Stroke
Intracranial Hemorrhages
Middle Cerebral Artery
Tissue Plasminogen Activator
Physicians
Ontario
Neuroimaging
Placebos
Therapeutics

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Silver, B., Demaerschalk, B. M., Merino, J. G., Wong, E., Tamayo, A., Devasenapathy, A., ... Hachinski, V. (2001). Improved outcomes in stroke thrombolysis with pre-specified imaging criteria. Canadian Journal of Neurological Sciences, 28(2), 113-119.

Improved outcomes in stroke thrombolysis with pre-specified imaging criteria. / Silver, B.; Demaerschalk, Bart M; Merino, J. G.; Wong, E.; Tamayo, A.; Devasenapathy, A.; O'Callaghan, C.; Kertesz, A.; Young, G. B.; Fox, A. J.; Spence, J. D.; Hachinski, V.

In: Canadian Journal of Neurological Sciences, Vol. 28, No. 2, 2001, p. 113-119.

Research output: Contribution to journalArticle

Silver, B, Demaerschalk, BM, Merino, JG, Wong, E, Tamayo, A, Devasenapathy, A, O'Callaghan, C, Kertesz, A, Young, GB, Fox, AJ, Spence, JD & Hachinski, V 2001, 'Improved outcomes in stroke thrombolysis with pre-specified imaging criteria', Canadian Journal of Neurological Sciences, vol. 28, no. 2, pp. 113-119.
Silver, B. ; Demaerschalk, Bart M ; Merino, J. G. ; Wong, E. ; Tamayo, A. ; Devasenapathy, A. ; O'Callaghan, C. ; Kertesz, A. ; Young, G. B. ; Fox, A. J. ; Spence, J. D. ; Hachinski, V. / Improved outcomes in stroke thrombolysis with pre-specified imaging criteria. In: Canadian Journal of Neurological Sciences. 2001 ; Vol. 28, No. 2. pp. 113-119.
@article{8fc8fa48b1644789a612446e5e439188,
title = "Improved outcomes in stroke thrombolysis with pre-specified imaging criteria",
abstract = "Background: A 1995 National Institute of Neurological Disorders (NINDS) study found benefit for intravenous tissue plasminogen activator (tPA) in acute ischemic stroke (AIS). The symptomatic intracranial hemorrhage (SICH) rate in the NINDS study was 6.4{\%}, which may be deterring some physicians from using this medication. Methods: Starting December 1, 1998, patients with AIS in London, Ontario were treated according to NINDS criteria with one major exception; those with approximately greater than one-third involvement of the idealized middle cerebral artery (MCA) territory on neuroimaging were excluded from treatment. The method used to estimate involvement of one-third MCA territory involvement bears the acronym ICE and had a median kappa value of 0.80 among five physicians. Outcomes were compared to the NINDS study. Results: Between December 1, 1998 and February 1,2000, 30 patients were treated. Compared to the NINDS study, more London patients were treated after 90 minutes (p<0.00001) and tended to be older. No SICH was observed. Compared to the treated arm of the NINDS trial, fewer London patients were dead or severely disabled at three months (p=0.04). Compared to the placebo arm of the trial, more patients made a partial recovery at 24 hours (p=0.02), more had normal outcomes (p=0.03) and fewer were dead or severely disabled at three months (p=0.004). Conclusions: The results of the NINDS study were closely replicated and, in some instances, improved upon in this small series of Canadian patients, despite older age and later treatment. These findings suggest that imaging exclusion criteria may optimize the benefits of tPA.",
author = "B. Silver and Demaerschalk, {Bart M} and Merino, {J. G.} and E. Wong and A. Tamayo and A. Devasenapathy and C. O'Callaghan and A. Kertesz and Young, {G. B.} and Fox, {A. J.} and Spence, {J. D.} and V. Hachinski",
year = "2001",
language = "English (US)",
volume = "28",
pages = "113--119",
journal = "Canadian Journal of Neurological Sciences",
issn = "0317-1671",
publisher = "Canadian Journal of Neurological Sciences",
number = "2",

}

TY - JOUR

T1 - Improved outcomes in stroke thrombolysis with pre-specified imaging criteria

AU - Silver, B.

AU - Demaerschalk, Bart M

AU - Merino, J. G.

AU - Wong, E.

AU - Tamayo, A.

AU - Devasenapathy, A.

AU - O'Callaghan, C.

AU - Kertesz, A.

AU - Young, G. B.

AU - Fox, A. J.

AU - Spence, J. D.

AU - Hachinski, V.

PY - 2001

Y1 - 2001

N2 - Background: A 1995 National Institute of Neurological Disorders (NINDS) study found benefit for intravenous tissue plasminogen activator (tPA) in acute ischemic stroke (AIS). The symptomatic intracranial hemorrhage (SICH) rate in the NINDS study was 6.4%, which may be deterring some physicians from using this medication. Methods: Starting December 1, 1998, patients with AIS in London, Ontario were treated according to NINDS criteria with one major exception; those with approximately greater than one-third involvement of the idealized middle cerebral artery (MCA) territory on neuroimaging were excluded from treatment. The method used to estimate involvement of one-third MCA territory involvement bears the acronym ICE and had a median kappa value of 0.80 among five physicians. Outcomes were compared to the NINDS study. Results: Between December 1, 1998 and February 1,2000, 30 patients were treated. Compared to the NINDS study, more London patients were treated after 90 minutes (p<0.00001) and tended to be older. No SICH was observed. Compared to the treated arm of the NINDS trial, fewer London patients were dead or severely disabled at three months (p=0.04). Compared to the placebo arm of the trial, more patients made a partial recovery at 24 hours (p=0.02), more had normal outcomes (p=0.03) and fewer were dead or severely disabled at three months (p=0.004). Conclusions: The results of the NINDS study were closely replicated and, in some instances, improved upon in this small series of Canadian patients, despite older age and later treatment. These findings suggest that imaging exclusion criteria may optimize the benefits of tPA.

AB - Background: A 1995 National Institute of Neurological Disorders (NINDS) study found benefit for intravenous tissue plasminogen activator (tPA) in acute ischemic stroke (AIS). The symptomatic intracranial hemorrhage (SICH) rate in the NINDS study was 6.4%, which may be deterring some physicians from using this medication. Methods: Starting December 1, 1998, patients with AIS in London, Ontario were treated according to NINDS criteria with one major exception; those with approximately greater than one-third involvement of the idealized middle cerebral artery (MCA) territory on neuroimaging were excluded from treatment. The method used to estimate involvement of one-third MCA territory involvement bears the acronym ICE and had a median kappa value of 0.80 among five physicians. Outcomes were compared to the NINDS study. Results: Between December 1, 1998 and February 1,2000, 30 patients were treated. Compared to the NINDS study, more London patients were treated after 90 minutes (p<0.00001) and tended to be older. No SICH was observed. Compared to the treated arm of the NINDS trial, fewer London patients were dead or severely disabled at three months (p=0.04). Compared to the placebo arm of the trial, more patients made a partial recovery at 24 hours (p=0.02), more had normal outcomes (p=0.03) and fewer were dead or severely disabled at three months (p=0.004). Conclusions: The results of the NINDS study were closely replicated and, in some instances, improved upon in this small series of Canadian patients, despite older age and later treatment. These findings suggest that imaging exclusion criteria may optimize the benefits of tPA.

UR - http://www.scopus.com/inward/record.url?scp=0035007970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035007970&partnerID=8YFLogxK

M3 - Article

C2 - 11383934

AN - SCOPUS:0035007970

VL - 28

SP - 113

EP - 119

JO - Canadian Journal of Neurological Sciences

JF - Canadian Journal of Neurological Sciences

SN - 0317-1671

IS - 2

ER -